New research suggests that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who halt conventional lifestyle plans.
Research printed in a prominent health publication points out that while overweight people frequently drop a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Individuals purchasing such treatments must be informed of the risk of rapid rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of recovery suggests a return to original weight within about one and a half years.
Analyzing Approaches
The analysis, which reviewed dozens of trials involving thousands of participants, compared the effects of these new drugs with conventional dieting.
The team note that people who lose weight through dieting generally see a more gradual creep back—approximately 100 grams monthly—post-intervention.
The Reason for the Quick Regain
Nutrition scientists suggest the mode of action of the drugs accounts for the accelerated regain.
These medications imitate a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing the hormone concentrations far above than the body's typical production may cause the body to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this medication results in hunger is unsuppressed, making excessive eating much more probable."
An Ongoing Disease?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts argue that, given the significant potential of relapse, the treatment should be considered life-long.
This view is reinforced by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," akin to managing diseases like hypertension.
Patient Accounts
People who have discontinued the jabs explain a intense resurgence of hunger.
"I experienced a trigger that goes on and I was suddenly extremely hungry," described one woman.
This challenge is worsened if individuals have not developed lasting lifestyle or habit modifications during treatment.
Growing Use
Recent estimates show that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.
- Use is more common among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, clinicians stress that while these medications are powerful agents for weight loss, they are not a magic cure and lasting health benefits relies on integrated behavioural changes.
